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efﬁcacy. CONCLUSIONS: In CLL patients, ﬁrst-line treatment
with R-FC in the observational setting signiﬁcantly extends life
expectancy and is a cost-effective alternative to FC.
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OBJECTIVES: To assess the lifetime cost-effectiveness (CE) of
oral topotecan (Hycamtin(r) Hard Capsules) plus best supportive
care (BSC) versus BSC alone in patients with relapsed SCLC in
the UK. METHODS: In an international randomised phase III
trial, patients with relapsed SCLC not considered as candidates
for standard intravenous therapy were randomly assigned to oral
topotecan (OT) plus BSC (n = 71) or to BSC alone (n = 70) and
followed until death. Median survival with BSC was 13.9 weeks
(95% CI, 11.1 to 18.6) and with OT, 25.9 weeks (95% CI, 18.3
to 31.6). Patients on OT had slower deterioration in health
related quality of life and greater symptom control. A CE model
using patient level data was developed to estimate the lifetime
incremental cost per quality adjusted life year (QALY) gained of
OT + BSC versus BSC alone. UK unit costs and an assumed drug
acquisition cost were included to estimate lifetime CE from the
perspective of the UK National Health Service (NHS). Outcomes
were measured in QALYs based on individual residual life
expectancy data and health related quality of life (EQ5D) col-
lected during the trial. The cost components were drug acquisi-
tion costs, drug administration costs, monitoring costs, costs of
treating haematological and non-haematological adverse events,
and costs of providing care in the additional months of life
attributable to OT + BSC. RESULTS: The base case estimate of
the incremental cost per QALY gained was £25,709. The results
were sensitive to the drug acquisition cost for OT. Subgroup
analysis showed that OT + BSC was more CE among patients
with rapid disease progression (i.e. treatment free interval <=60
days) (cost/QALY = £16,957), with worse performance status
(i.e. PS 2) (£24,783), and with no liver metastasis (£20,345).
CONCLUSIONS: In patients with relapsed SCLC OT + BSC
represents a cost-effective treatment option versus BSC alone
from the perspective of the UK NHS.
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OBJECTIVES: Despite the high incidence of NSCLC, little is
known about associated economic burdens experienced by
patients and caregivers. In a longitudinal study of newly diag-
nosed stage IV NSCLC patients we calculated estimates of out-
of-pocket costs (OPC) and time costs (TC) for patients and
caregivers. We also explored the relationship between OPC and
sociodemographic and clinical factors. METHODS: Patients
and their surrogates were asked to report OPC and TC in
monthly diaries and surveys. Monthly costs were compared in 2
disease phases: terminal phase (TP) within 2 months of death,
and initial phase (IP) from diagnosis until 2 months before death
(2007 US $). RESULTS: Among 196 patients, 129 received initial
chemotherapy and 67 received best supportive care. Mean age
was 59 years and median income was $60,000; 40% were
employed. Initial treatment choice was not associated with OPC,
but phase of illness was. Monthly mean OPCs were $372 and
$582 (p-value = 0.02) during IP and TP. Prescription medications
and transportation accounted for 22% v. 27%, and 15% v. 37%,
of total OPC in IP and TP, respectively. In TP, mean monthly
wage losses of $1835 for patients and $419 for caregivers were
reported. 87 respondents (48%) reported usage of complemen-
tary and alternative therapy, at a mean monthly cost of $107
among users. 86% of surrogates reported some effect of caregiv-
ing on work, including job loss in 6%. Costs of lost leisure time
for caregivers were signiﬁcantly higher in TP compared to IP, at
$3682 vs. $1579 (p-value = 0.003). CONCLUSIONS: OPC and
TC represent a substantial ﬁnancial burden on patients and car-
egivers. A vast majority of caregivers report adverse work
impact. These results support the need for programs aimed at
alleviating the economic burden stemming from care-related
activities that are increasingly being shifted towards informal
caregivers and patients.
PCN73
DEVELOPING A COMPREHENSIVE COSTSTOOLKITTO
FACILITATE ECONOMIC EVALUATIONS OF CANCER CARE
IN FRANCE
Baffert S1, Coudray-Omnès C2, Livartowski A1
1Institut Curie, Paris, France, 2Roche, Neuilly sur Seine, France
Health care costs are virtual and depend upon the criteria chosen.
Costs considered for economic evaluations vary according to the
objective of the study, comparators, analysis perspective, time
horizon and stage of the disease. OBJECTIVES: Our research
objective is to create a toolkit compiling relevant and exhaustive
information about costs needed to conduct an economic evalu-
ation for cancer. METHODS: Economic French data were exten-
sively collected within Internet sites, French ofﬁcial journals,
health insurance and hospital databases, IRDES, INSEE, per-
sonal contacts with health economics professionals. We check-
listed the costs to build a table showing the different type of costs,
how and when these costs can be used, where they can be found.
Consistent references, data sources are included. RESULTS:
Cancer costs can be split into induced and avoided costs. If costs
of chemotherapy (acquisition, administration) are usually well
known, others are not easily comprehensive and accessible such
as: costs of complications, adverse events, transportations, costs
of follow-up, of time lost, of ambulatory care, costs of adapting
home, sick pay for medical disorders . . . For example, to calcu-
late the cost of loss of productivity, we need French average
annual income. Available INSEE data provide average incomes
per year, per sector (private or public), per social and work
classes, per sex, per age. If these items are perfectly identiﬁed a
priori they can be directly collected in Case Report Form to
enhance prospective data management. In the same way, costs of
transportation could be easily available indeed they are calcu-
lated with a scale established by ministerial decree. CONCLU-
SIONS: Clearly identifying and making easily available economic
data could reduce process of economic assessment. Taking into
account standard costs would simplify economics studies and
increase their production. Comprehensive and exhaustive costs
tables are intended to be useful for decision-makers, in particular
for Health Technology Assessment.
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